The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Cosentyx (secukinumab) on April 17, 2026. This regulatory action, designated as a supplemental application for efficacy (BLA 125504 S-97), was sponsored by Novartis Pharmaceuticals Corporation.
Background
Cosentyx, known generically as secukinumab, is a biologic medication that has been previously approved for various indications. A supplemental application for efficacy typically signifies that the manufacturer has submitted new clinical data to the FDA, demonstrating the drug's effectiveness for an additional use, a new patient population, or an expanded treatment scope for an existing indication. These applications are crucial for broadening the utility of established therapies.
What this means
This supplemental approval for Cosentyx (secukinumab) indicates that the FDA has reviewed and accepted new evidence supporting the drug's effectiveness in a specific context. While the precise new indication or patient population is not detailed in the provided information, such approvals generally lead to expanded treatment options for healthcare providers and patients. Clinicians may anticipate updated prescribing information that reflects the new efficacy data, potentially allowing Cosentyx to be used for a wider range of conditions or in different patient groups than before. This process ensures that medications are continually evaluated and their benefits are extended to more individuals where appropriate.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125504 S-97 for Cosentyx (secukinumab) was documented on April 17, 2026, on accessdata.fda.gov.